Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Anatara Lifesciences Ltd ( (AU:ANR) ) is now available.
Anatara Lifesciences Ltd has reported promising pre-clinical results for its Anti-Obesity Project, with the candidate compound AOC showing significant potential in managing weight reduction and controlling weight gain after cessation of weight loss treatments. Although the Mechanism of Action studies have faced delays due to international supply issues, the company remains committed to advancing its research and exploring further commercial opportunities. The project aims to develop an oral complementary medication to assist in weight management, and Anatara is actively pursuing business development discussions to capitalize on these findings.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products aimed at addressing significant unmet needs in human health. The company focuses on creating solutions in the healthcare sector, particularly targeting weight management and gastrointestinal health.
Average Trading Volume: 1,086,836
Technical Sentiment Signal: Sell
Current Market Cap: A$3.76M
Find detailed analytics on ANR stock on TipRanks’ Stock Analysis page.